Sukumar Nagendran - Jan 2, 2024 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
President and Head of R&D, Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:42 PM
Previous filing
Dec 18, 2023
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Award $0 +864K +2523.28% $0.00 898K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +864K $0.00 864K Jan 2, 2024 Common Stock 864K $1.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
F2 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.